{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:13:10Z","timestamp":1786993990177,"version":"build-2736575974"},"reference-count":33,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.mayocp.2024.10.026","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T07:17:37Z","timestamp":1751440657000},"page":"1345-1359","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Plasma Levels of Fibroblast Growth Factor 21 and Adverse Kidney Outcomes"],"prefix":"10.1016","volume":"100","author":[{"given":"Hee Byung","family":"Koh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo Jeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung Woo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Ik","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Tak","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Hyun","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-Wook","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7923-5635","authenticated-orcid":false,"given":"Seung Hyeok","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10225","key":"10.1016\/j.mayocp.2024.10.026_bib1","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","year":"2020","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.mayocp.2024.10.026_bib2","doi-asserted-by":"crossref","first-page":"e0158765","DOI":"10.1371\/journal.pone.0158765","article-title":"Global prevalence of chronic kidney disease - a systematic review and meta-analysis","volume":"11","author":"Hill","year":"2016","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.mayocp.2024.10.026_bib3","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/ndt\/gfz260","article-title":"Chronic kidney disease progression and mortality risk profiles in Germany: results from the Chronic Kidney Disease Outcomes and Practice Patterns Study","volume":"35","author":"Reichel","year":"2020","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"10.1016\/j.mayocp.2024.10.026_bib4","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1038\/s41591-019-0627-8","article-title":"Glomerular filtration rate by differing measures, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease","volume":"25","author":"Lees","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.mayocp.2024.10.026_bib5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-physiol-021115-105339","article-title":"Understanding the physiology of FGF21","volume":"78","author":"Fisher","year":"2016","journal-title":"Annu Rev Physiol"},{"issue":"12","key":"10.1016\/j.mayocp.2024.10.026_bib6","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.1210\/en.2008-0816","article-title":"Fibroblast growth factor 21 corrects obesity in mice","volume":"149","author":"Coskun","year":"2008","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.mayocp.2024.10.026_bib7","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.cmet.2013.08.005","article-title":"The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes","volume":"18","author":"Gaich","year":"2013","journal-title":"Cell Metab"},{"issue":"5","key":"10.1016\/j.mayocp.2024.10.026_bib8","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.2337\/db07-1476","article-title":"Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans","volume":"57","author":"Zhang","year":"2008","journal-title":"Diabetes"},{"issue":"12","key":"10.1016\/j.mayocp.2024.10.026_bib9","doi-asserted-by":"crossref","first-page":"e15534","DOI":"10.1371\/journal.pone.0015534","article-title":"Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile","volume":"5","author":"Lin","year":"2010","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.mayocp.2024.10.026_bib10","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.2337\/dc09-0684","article-title":"Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance","volume":"32","author":"Chavez","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.mayocp.2024.10.026_bib11","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.metabol.2018.11.006","article-title":"High plasma FGF21 levels predicts major cardiovascular events in patients treated with atorvastatin (from the Treating to New Targets [TNT] study)","volume":"93","author":"Ong","year":"2019","journal-title":"Metabolism"},{"issue":"12","key":"10.1016\/j.mayocp.2024.10.026_bib12","doi-asserted-by":"crossref","first-page":"4886","DOI":"10.1210\/jc.2016-2308","article-title":"Association between serum fibroblast growth factor 21 and mortality among patients with coronary artery disease","volume":"101","author":"Li","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.mayocp.2024.10.026_bib13","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1007\/s00125-015-3652-2","article-title":"Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study","volume":"58","author":"Ong","year":"2015","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.mayocp.2024.10.026_bib14","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s00125-014-3458-7","article-title":"The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study","volume":"58","author":"Ong","year":"2015","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.mayocp.2024.10.026_bib15","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1210\/jc.2014-3465","article-title":"Circulating fibroblast growth factor 21 levels predict progressive kidney disease in subjects with type 2 diabetes and normoalbuminuria","volume":"100","author":"Lee","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.mayocp.2024.10.026_bib16","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/ki.2015.199","article-title":"Biomarkers of rapid chronic kidney disease progression in type 2 diabetes","volume":"88","author":"Looker","year":"2015","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.mayocp.2024.10.026_bib17","doi-asserted-by":"crossref","first-page":"12425","DOI":"10.1038\/s41598-018-30744-8","article-title":"Circulating fibroblast growth factor 21 is associated with subsequent renal injury events in patients undergoing coronary angiography","volume":"8","author":"Wu","year":"2018","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.mayocp.2024.10.026_bib18","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1093\/ndt\/gfy120","article-title":"Relationship of fibroblast growth factor 21 with kidney function and albuminuria: multi-ethnic study of atherosclerosis","volume":"34","author":"Anuwatmatee","year":"2019","journal-title":"Nephrol Dial Transplant"},{"issue":"50","key":"10.1016\/j.mayocp.2024.10.026_bib19","doi-asserted-by":"crossref","first-page":"e28238","DOI":"10.1097\/MD.0000000000028238","article-title":"Association of serum fibroblast growth factor 21 with kidney function in a population-based Chinese cohort","volume":"100","author":"Zhang","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.mayocp.2024.10.026_bib20","doi-asserted-by":"crossref","first-page":"e1001779","DOI":"10.1371\/journal.pmed.1001779","article-title":"UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age","volume":"12","author":"Sudlow","year":"2015","journal-title":"PLoS Med"},{"issue":"7982","key":"10.1016\/j.mayocp.2024.10.026_bib21","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41586-023-06592-6","article-title":"Plasma proteomic associations with genetics and health in the UK Biobank","volume":"622","author":"Sun","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.mayocp.2024.10.026_bib22","doi-asserted-by":"crossref","first-page":"154738","DOI":"10.1016\/j.metabol.2021.154738","article-title":"FGF21 and chronic kidney disease","volume":"118","author":"Salgado","year":"2021","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.mayocp.2024.10.026_bib23","doi-asserted-by":"crossref","first-page":"15973","DOI":"10.1038\/s41598-018-34238-5","article-title":"Fibroblast growth factor binding protein 3 (FGFBP3) impacts carbohydrate and lipid metabolism","volume":"8","author":"Tassi","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.mayocp.2024.10.026_bib24","doi-asserted-by":"crossref","first-page":"100168","DOI":"10.1016\/j.mcpro.2021.100168","article-title":"Proximity extension assay in combination with next-generation sequencing for high-throughput proteome-wide analysis","volume":"20","author":"Wik","year":"2021","journal-title":"Mol Cell Proteomics"},{"issue":"1","key":"10.1016\/j.mayocp.2024.10.026_bib25","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1038\/s41467-021-22767-z","article-title":"Next generation plasma proteome profiling to monitor health and disease","volume":"12","author":"Zhong","year":"2021","journal-title":"Nat Commun"},{"issue":"14","key":"10.1016\/j.mayocp.2024.10.026_bib26","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1002\/sim.5647","article-title":"A unified inference procedure for a class of measures to assess improvement in risk prediction systems with survival data","volume":"32","author":"Uno","year":"2013","journal-title":"Stat Med"},{"issue":"21","key":"10.1016\/j.mayocp.2024.10.026_bib27","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1001\/jama.2019.17379","article-title":"Development of risk prediction equations for incident chronic kidney disease","volume":"322","author":"Nelson","year":"2019","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.mayocp.2024.10.026_bib28","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.2337\/db10-0193","article-title":"Obesity is a fibroblast growth factor 21 (FGF21)-resistant state","volume":"59","author":"Fisher","year":"2010","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.mayocp.2024.10.026_bib29","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1210\/en.2010-1262","article-title":"Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance","volume":"153","author":"Hale","year":"2012","journal-title":"Endocrinology"},{"issue":"9","key":"10.1016\/j.mayocp.2024.10.026_bib30","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1210\/en.2012-2276","article-title":"Fibroblast growth factor 21 improves insulin resistance and ameliorates renal injury in db\/db mice","volume":"154","author":"Kim","year":"2013","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.mayocp.2024.10.026_bib31","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12896-017-0368-z","article-title":"Potent long-acting rhFGF21 analog for treatment of diabetic nephropathy in db\/db and DIO mice","volume":"17","author":"Zhao","year":"2017","journal-title":"BMC Biotechnol"},{"issue":"7","key":"10.1016\/j.mayocp.2024.10.026_bib32","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/dme.13641","article-title":"Sex modulates the association of fibroblast growth factor 21 with end-stage renal disease in Asian people with type 2 diabetes: a 6.3-year prospective cohort study","volume":"35","author":"Liu","year":"2018","journal-title":"Diabet Med"},{"issue":"11","key":"10.1016\/j.mayocp.2024.10.026_bib33","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1016\/j.metabol.2010.03.018","article-title":"Serum fibroblast growth factor-21 concentration is associated with residual renal function and insulin resistance in end-stage renal disease patients receiving long-term peritoneal dialysis","volume":"59","author":"Han","year":"2010","journal-title":"Metabolism"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619624006517?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619624006517?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:30:21Z","timestamp":1756168221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619624006517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0025619624006517"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2024.10.026","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma Levels of Fibroblast Growth Factor 21 and Adverse Kidney Outcomes","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2024.10.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}